Alpha-Glucosidase Inhibitors and Others

Alpha-glucosidase inhibitors — acarbose and miglitol — are low-yield but reliably tested on USMLE Step 1 in one specific, high-yield way: the hypoglycemia treatment trap. The mechanism is straightforward: these drugs sit in the brush border of the small intestine and competitively inhibit alpha-glucosidases, the enzymes that break disaccharides and oligosaccharides into absorbable monosaccharides. The result is delayed carbohydrate absorption and blunted postprandial glucose spikes. They don't cause hypoglycemia on their own — but when combined with other agents that do (sulfonylureas, insulin), the hypoglycemia they cause requires a specific treatment.

The other agents in this category — pramlintide (amylin analog, slows gastric emptying, suppresses glucagon) and bromocriptine QR (dopamine agonist, reduces postprandial glucose) — are even lower yield. Know their classes and general mechanisms but don't over-invest. USMLE Step 1 questions in this space are almost exclusively about acarbose mechanics and consequences.

What makes this topic tricky isn't the mechanism — it's the downstream clinical logic. Students who memorize 'acarbose delays carb absorption' often don't take that reasoning far enough to answer applied questions correctly. The GI side effects (flatulence, bloating, diarrhea) are a direct consequence of the mechanism: undigested carbs pass to the colon where bacteria ferment them. And the hypoglycemia correction rule is a direct consequence too. Both are the same story — unabsorbed carbohydrates — just playing out in different clinical contexts.